Related Experiment Videos
Principles of antibody therapy
S J Russell1, M B Llewelyn, R E Hawkins
1MRC Centre, Cambridge.
BMJ (Clinical Research Ed.)
|December 5, 1992
Summary
Monoclonal antibodies offer targeted therapies with fewer side effects. Advances in antibody design and engineering are expanding their use in treating various conditions, from transplant rejection to cancer.
Area of Science:
- Immunology
- Biotechnology
- Pharmacology
Background:
- Monoclonal antibodies (mAbs) are crucial in modern medicine, but their success hinges on effective design.
- Target selection is paramount, as antibody properties can be genetically modified.
- Current applications include immunosuppression and potential treatments for infections and cancers.
Purpose of the Study:
- To review the design principles and clinical applications of monoclonal antibodies.
- To highlight the expanding role of antibody engineering in therapeutic development.
- To discuss the challenges and future prospects of monoclonal antibodies in medicine.
Main Methods:
- Review of existing literature on monoclonal antibody design and clinical trials.
- Analysis of therapeutic successes and limitations in various disease areas.
- Discussion of emerging trends in antibody engineering and target identification.
Main Results:
- Monoclonal antibodies targeting lymphocyte antigens provide less toxic immunosuppression, exemplified by their use in renal transplant rejection.
- Clinical trials for septic shock and development for pathogens like herpes simplex virus are underway.
- While cancer treatment faces challenges due to tumor penetration, blood cancer therapies show promise, with human antibodies against B cell malignancies in clinical testing.
Conclusions:
- Effective monoclonal antibody design is essential for clinical success.
- Targeting lymphocyte antigens offers a promising avenue for less toxic immunosuppression.
- Continued advancements in antibody engineering and a deeper understanding of immune responses will likely increase the clinical utility of monoclonal antibodies across diverse diseases.